April Fund Ltd21 April Fund... Net Worth

The estimated Net Worth of April Fund Ltd21 April Fund... is at least $22.6 Milión dollars as of 11 January 2016. April Fund owns over 300,100 units of Durect Corp stock worth over $22,579,027 and over the last 9 years April sold DRRX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

April Fund DRRX stock SEC Form 4 insiders trading

April has made over 2 trades of the Durect Corp stock since 2016, according to the Form 4 filled with the SEC. Most recently April bought 300,100 units of DRRX stock worth $411,137 on 11 January 2016.

The largest trade April's ever made was buying 300,100 units of Durect Corp stock on 11 January 2016 worth over $411,137. On average, April trades about 300,100 units every 0 days since 2016. As of 11 January 2016 April still owns at least 14,381,546 units of Durect Corp stock.

You can see the complete history of April Fund stock trades at the bottom of the page.

Insiders trading at Durect Corp

Over the last 21 years, insiders at Durect Corp have traded over $528,010 worth of Durect Corp stock and bought 19,954,650 units worth $23,296,708 . The most active insiders traders include April Fund Ltd21 April Fund..., Eagle Investment Management... a Felix Theeuwes. On average, Durect Corp executives and independent directors trade stock every 55 days with the average trade being worth of $468,485. The most recent stock trade was executed by Judith J. Robertson on 18 August 2022, trading 80,942 units of DRRX stock currently worth $68,801.

What does Durect Corp do?

durect is a specialty pharmaceuticals company with expertise in drug discovery, drug delivery and drug development, applying those skills primarily to therapeutics in the fields of pain management, acute organ injury and metabolic diseases. durect’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. late stage development programs of this nature include remoxy® and posidur™. durect’s epigenomic regulator program includes the lead molecule dur-928 in phase 1 clinical testing. dur-928 is an endogenous small molecule that is an epigenomic modulator of cellular activities involved in lipid homeostasis, metabolic disease, inflammation and cell survival. for more information, please visit www.durect.com. we also manufacture and sell two commercial product lines: • alzet® osmotic pumps use

Complete history of April Fund stock trades at Durect Corp

Durect Corp executives and stock owners

Durect Corp executives and other stock owners filed with the SEC include:

• Dr. James E. Brown D.V.M.,
  Co-Founder, CEO, Pres & Director
• Michael H. Arenberg,
  CFO & Sec.
• Dr. Norman L. Sussman,
  Chief Medical Officer
• Judy R. Joice,
  Sr. VP of Operations & Corp. Quality Assurance
• Dr. Su Il Yum Ph.D.,
  Exec. Officer
• Jian Li M.B.A.,
  VP of Fin. & Corp. Controller
• Dr. WeiQi Lin,
  Exec. VP of R&D and Principal Scientist
• Steve Helmer J.D.,
  VP & Chief Patent Counsel
• Dr. Andrew R. Miksztal,
  VP of Pharmaceutical R&D and Principal Scientist
• Judy R Joice,
  Sr. VP Operations & Corp QA
• April Fund Ltd21 April Fund...,
  
• April Fund Ltd Arnhold & S....,
  
• Dave Hoffmann,
  Director
• Jon S Saxe,
  Director
• Terrence F Blaschke,
  Director
• Jay Shepard,
  Director
• Armand Neukermans,
  Director
• Simon X Benito,
  Director
• Eagle Investment Management...,
  
• April Fund Ltd21 April Fund...,
  
• Matthew J Hogan,
  Chief Financial Officer
• Michael Arenberg,
  Chief Financial Officer
• Judith J. Robertson,
  Director
• Gail M Farfel,
  Director
• Paula V Mendenhall,
  Sr. VP of Operations
• Su Il Yum,
  Exec. VP Pharm./R&D
• Michael D Casey,
  Director
• Joseph William Stauffer,
  CMO and Exec.VP Corp. Strategy
• Jean I Liu,
  Senior VP & General Counsel
• Edward M Gillis,
  VP Engineering
• Thomas A Schreck,
  Chief Financial Officer
• Michael J Taylor,
  VP, Non Clinical Research
• Felix Theeuwes,
  Chairman and CSO
• Arthur J Tipton,
  Sr.VP Bioerodible Product Dev.
• Timothy S Nelson,
  Senior VP Business & Dev.
• Peter Langecker,
  Chief Medical Officer
• Tai Wah Chan,
  VP Pharmaceutical Research
• Steven Halladay,
  VP Clinical and Regulatory
• Li Jian,
  VP Finance and Controller
• Lp Bleichroeder,
  10% owner
• Eagle Investment Management...,
  
• Mohammad Azab,
  Director
• Gail J Maderis,
  Director
• Peter S Garcia,
  Director
• James E Brown,
  President & CEO
• Timothy M. Papp,
  Chief Financial Officer
• Norman Sussman,
  Chief Medical Officer